Le Lézard
Classified in: Health, Business
Subjects: PDT, DIV, JVN, FDA, MAT

PAOG Adds Nutraceutical Pathway To Pharmaceutical Cannabis Strategy

SANDUSKY, Ohio, Oct. 29, 2020 /PRNewswire/ -- PAO Group, Inc. (USOTC: PAOG) today announced adding a nutraceutical development pathway to its existing pharmaceutical cannabis drug development strategy.  Last week, PAOG announced a master services agreement with a clinical research organization (CRO) in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  More details on the CRO contract are coming soon.  Now PAOG has committed to simultaneously launching a nutraceutical development initiative drawing on its respiratory therapy cannabis extract treatment research.  The nutraceutical development pathway is anticipated to rapidly progress PAOG to a revenue stream while continuing to pursue the pharmaceutical development pathway.  PAOG anticipates soon announcing a nutraceutical development contract.

Separately, PAOG confirms plans with Puration, Inc. (USOTC: PURA) to publish a joint update tomorrow, Friday, October 30, 2020 on the progress toward making PURA shareholders PAOG shareholders.  PAOG recently acquired PURA's cannabis cultivation operation in a deal that included the issuance of PAOG stock to PURA shareholders in a dividend distribution.  Management of the two companies will provide a progress update on the dividend process tomorrow.


Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.


Contact Us:
Jim DiPrima


SOURCE PAO Group, Inc.

These press releases may also interest you

at 16:45
908 Devices, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to...

at 16:35
CB2 Insights (CSE:CBII; OTCQB:...

at 16:15
Dr. Paul Lange, M.D., F.C.C.P., has been named medical director at Donor Alliance, the federally designated organ procurement organization serving Colorado and most of Wyoming. A board certified physician in pulmonary and critical care medicine,...

at 16:00
Amgen will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday, Dec. 1, 2020. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief...

at 16:00
E-Z-C Pak, the first physician formulated immune support pack composed of Echinacea, Zinc, and Vitamin C designed to reduce antibiotic overuse in cold and flu has surged in demand amid the COVID-19 outbreak. Company spokesperson Julianne Jahn...

at 15:28
Vivera Pharmaceuticals and Burkhan World today announce financial backing by JR Dallas Wealth Management in support of Vivera's global growth strategies. This ongoing partnership will provide financial services ? including debt and equity backing ?...

News published on 29 october 2020 at 10:14 and distributed by: